Compare Sana Biotechnology Inc (SANA) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.33. The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| SANA | YMAG | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $5.92 | $15.98 |
52-Week Low | $2.68 | $10.76 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
YMAG trades at $11.29, down 2.59% today, with technical indicators showing a bullish overall signal despite mixed oscillators. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.07 to $0.40 per share. Recent news highlights YieldMax's distribution announcements and analysis of the fund's option income strategy performance.
The fund's structured option strategy provides high income potential but faces NAV stability challenges during earnings volatility. Key risks include concentrated exposure to Magnificent Seven stocks and option strategy complexity. Technical support sits at $11-12 levels while the bullish moving average trend suggests potential upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
